Geographic disparities in head and neck cancer mortality and place of death in the United States from 2003 to 2019.

Authors

Nino Balanchivadze

Nino Balanchivadze

Department of Hematology and Oncology, Henry Ford Cancer Institute, Detroit, MI

Nino Balanchivadze, Amanda L. Blackford, Ling Huang, Vivian V. Altiery Altiery De Jesus, Michael Hwang, Ramy Sedhom, Arjun Gupta, S. M. Qasim Hussaini

Organizations

Department of Hematology and Oncology, Henry Ford Cancer Institute, Detroit, MI, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, Johns Hopkins School of Medicine, Baltimore, MD, Johns Hopkins Bayview Medical Center, Baltimore, MD, New Jersey Medical School, Middletown, NJ, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD

Research Funding

No funding received
None.

Background: Survival has significantly improved for patients with head and neck cancer (HNC) in the last decade in the US. Unfortunately, social determinants of health continue to impact patient outcomes. HPV vaccine uptake and access to quality end-of-life care vary notably between geographic areas. We investigated potential disparities in rural-urban age-adjusted mortality rates (AAMRs) and place of death for individuals with head and neck cancer (HNC). Methods: We used the CDC WONDER database to identify patients who died from HNC between 2003 and 2019 within the following 2013 US Census population classifications: large metropolitan (≥1 million), medium/small metropolitan (50,000-999,999), and rural areas (< 50,000). AAMR (per 100,000 individuals) was stratified by geographic area, age, and race/ethnicity. Annual percentage changes (APC) in AAMR were estimated with linear regression models of the log-scale AAMR (including population size as weights) and differential changes over time by geographic area were assessed with interaction tests. Odds ratios (OR) for the association between each place of death and individual-level characteristics were calculated using logistic regression, adjusting for year of death. Results: From 2003 to 2019, 221,861 deaths related to HNC occurred (48.5% large metropolitan, 31.9% medium/small metropolitan, 19.7% rural). Total AAMR declined from 6.7 to 5.8 during this period. Rural areas consistently had a higher AAMR and also slower annual improvement over time (APC –0.11; 95% CI, –0.36 to 0.13; p < 0.001) than medium/small metropolitan (APC –0.51; 95% CI, –0.78 to 0.24) and large metropolitan areas (APC –1.19; 95% CI, –1.39 to –1.0; p < 0.001). Non-Hispanic (NH) Black patients had the highest overall AAMR, but quickest annual improvement (APC –2.91; 95% CI, –3.28 to –2.55; p < 0.001) compared to Hispanic (APC -1.42, 95% CI, -1.9 to -0.93) and NH White patients (APC –0.26, 95% CI, –0.44 to 0.07). Individuals in rural areas died less often in a hospice facility (5.6% rural vs 10.8% large metropolitan vs 12% medium/small metropolitan) and slightly more often at home (46.3% rural vs 40.1% large metropolitan vs 43.7% medium/small metropolitan). Relative to patients in rural areas, patients in large metropolitan (OR 1.77; 95% CI, 1.74 to 1.81) and medium/small metropolitan areas (OR 2.27; 95% CI, 2.23 to 2.31) had higher odds of dying in a hospice facility compared to a medical facility. Conclusions: Rural residents with HNC experienced higher mortality rates and had lesser improvement compared to urban areas, with notable sociodemographic differences, and disparities in place of death. Public health interventions to combat health inequities for patients with HNC are required. Further, as EOL care is increasingly complex and the role of unpaid caregiving burdensome, policy interventions targeted to support disadvantaged populations and communities are urgent and necessary.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience

Sub Track

Cancer Outcome Disparities

Citation

J Clin Oncol 40, 2022 (suppl 28; abstr 161)

DOI

10.1200/JCO.2022.40.28_suppl.161

Abstract #

161

Poster Bd #

E30

Abstract Disclosures

Similar Abstracts

First Author: Melissa R Rosen

Abstract

2023 ASCO Quality Care Symposium

Evaluation of the contribution of county characteristics to the rural mortality disparity in cancer.

First Author: Jeffrey Franks

Abstract

2024 ASCO Quality Care Symposium

Impact of a mortality prediction tool on end-of-life (EOL) quality measures.

First Author: Jody S. Garey

First Author: Kelli Clemons